Information Provided By: 
Fly News Breaks for January 22, 2018
ESPR
Jan 22, 2018 | 05:06 EDT
Citi analyst Joel Beatty downgraded Esperion Therapeutics to Neutral while raising his price target for the shares to $96 from $77. Post the the bempedoic acid Phase 3 data in March, the stock will trade primary based on investor sentiment about whether Esperion will be acquired, Beatty tells investors in a research note. He's cautious about the likelihood of the company being acquired over the next 12 months.
News For ESPR From the Last 2 Days
There are no results for your query ESPR
